PALLAS: PALbociclib CoLlaborative Adjuvant Study | Clinical Research Studies Listing

Recruiting

18 years - 99 years

All

Phase 3

24 participants needed

Brief description of study

The purpose of this study is to compare any good and bad effects of using 2 years of the investigational drug Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood that invasive breast cancer returns.

Detailed description of study

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Breast cancer, breast, hormone
Age: 18 years - 99 years
Gender: All

Updated on 19 Feb 2024. Study ID: 825836

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.